Wutah pendapatan taun lumaku: Oncternal Corp (ONCT)

Logo perusahaan publik oncternal.com (ONCT)

Oncternal Therapeutics is penetrating the solid and hematologic tumor therapy market, leveraging unique patents in receptor inhibitors. This daily price chart of the 12-month revenue trajectory on the GURU.Markets portal shows the value has stabilized at -65.40. Positive catalysts include the success of zilovertamab in treating lymphomas, the development of CAR-T technologies, and support from specialized institutions.

Oncternal Therapeutics (ONCT): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 20.02.2024

Oncternal Therapeutics - rincian analitis lan metrik utama (ONCT)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:Oncternal
Produk merek Oncternal Corp

To objectively evaluate the issuer, it is essential for the manager to track revenue dynamics over the last twelve months, where daily growth recalculations allow for the differentiation of random fluctuations from a systemic decline. Analyzing the annual growth rate of trailing twelve-month (LTM) revenue is critical for Oncternal Therapeutics (ONCT), as geopolitical tensions and sanction-related logistics restrictions for reagents could slow the market launch of drugs, which would be reflected in this indicator.

Karo sapa Oncternal Therapeutics saingan

Incyte Pharma - Wutah dodolan YoY sajrone rolas wulan kepungkur|HUTCHMED Corp - Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku Nuvation Bio Inc.|DAWN: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Monopar Pharma MNPR|Wutah pendapatan YoY sajrone 12 wulan kepungkur INBX|Wutah pendapatan taun lumaku I-Mab Biopharma IMAB|Wutah pendapatan YoY sajrone 12 wulan kepungkur FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Nuvectis Pharma, Inc. - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CHRS (Coherus BioSciences)|Corbus Pharma - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur CRDF (cardiffoncology.com)|BYSI: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku BioAtla Corp (BCAB)|Wutah dodolan YoY sajrone rolas wulan kepungkur Lixte Biotechnology Holdings, Inc.|CTXR: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) CLRB|Wutah dodolan YoY (TTM) BioLineRx Corporation (BLRX)|Wutah dodolan YoY sajrone rolas wulan kepungkur Can-Fite BioPharma, Ltd. CANF|APRE (aprea.com) - Wutah dodolan taun lumaku|KZIA: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku Silexion Therapeutics|NuCana plc (NCNA) - Wutah dodolan YoY sajrone rolas wulan kepungkur|Wutah pendapatan YoY sajrone 12 wulan kepungkur Chimerix, Inc|Wutah pendapatan YoY sajrone 12 wulan kepungkur CYCC|Wutah pendapatan YoY sajrone 12 wulan kepungkur G1 Therapeutics (GTHX)|Wutah dodolan YoY sajrone rolas wulan kepungkur Kronos Bio Corporation (KRON)|Kintara - Wutah dodolan YoY sajrone 12 wulan kepungkur|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur